Ezetimibe Treatment Lowers Indicators of Oxidative Stress in Hypercholesterolemic Subjects with High Oxidative Stress
Ezetimibe Treatment Lowers Indicators of Oxidative Stress in Hypercholesterolemic Subjects with High Oxidative Stress
复制标题
DOI：
10.1007/s11745-011-3539-z
复制
发表时间：
2011-04-01
期刊：
影响因子：
1.9
通讯作者：
Liberopoulos, Evangelos N.
中科院分区：
文献类型：
--
作者：
Kostapanos, Michael S.;Spyrou, Athanasia T.;Liberopoulos, Evangelos N.
依折麦布可有效降低低密度脂蛋白胆固醇（LDL-C）。在本研究中，我们检验了依折麦布单药治疗也可能降低高胆固醇血症受试者氧化应激标志物的假设。高胆固醇血症且无心血管疾病证据的受试者被随机分配至开放标签依折麦布单药治疗10 mg/天（EZT组）或治疗性生活方式改变（TLC组）。在基线和治疗后12周，盲法测定血清脂蛋白和载脂蛋白水平以及氧化应激参数，包括氧化LDL（ox-LDL）、8-异前列腺素（8-epiPGF 2a）和活性氧代谢产物（d-ROM）水平。共纳入60例患者;每组30例。尽管EZT组中ox-LDL水平显著降低（降低20.8%，与基线相比p < 0.001;与TLC组相比p < 0.001），但依折麦布治疗后ox-LDL与LDL-C的比值未发生变化。在EZT组中未观察到8-epiPGF 2a和d-ROM水平的显著变化。值得注意的是，在基线时表现出“高氧化应激”的EZT组患者中，8-epiPGF 2a和d-ROM水平显著降低（分别降低20.4%和18.2%，p < 0.01）。TLC组中未观察到任何氧化应激参数变化。依折麦布可降低高胆固醇血症受试者的氧化应激标志物。这种益处在基线时表现出“高氧化应激”的患者中可能更深刻。
Ezetimibe effectively reduces low-density lipoprotein cholesterol (LDL-C). In this study, we tested the hypothesis that ezetimibe monotherapy may also decrease markers of oxidative stress in subjects with hypercholesterolemia. Subjects with hypercholesterolemia and no evidence of cardiovascular disease were randomly allocated to open-label ezetimibe monotherapy 10 mg/day (EZT group) or therapeutic lifestyle changes (TLC group). At baseline and 12 weeks post-treatment serum lipoprotein and apolipoprotein levels as well as oxidative stress parameters, including oxidized LDL (ox-LDL), 8-isoprostanes (8-epiPGF2a) and reactive oxygen metabolites (d-ROMs) levels, were blindly determined. A total of 60 patients were included; 30 in each group. Despite a significant decrease in ox-LDL levels (by 20.8%, p < 0.001 vs. baseline; p < 0.001 vs. TLC group) in the EZT group no change in the ratio ox-LDL to LDL-C was noticed following ezetimibe treatment. No significant change in 8-epiPGF2a and d-ROMs levels was observed in the EZT group. Of note, a significant decrease in 8-epiPGF2a and d-ROMs levels (by 20.4% and 18.2%, respectively, p < 0.01 vs. baseline for both), was noted among patients in the EZT group who exhibited 'high oxidative stress' at baseline. No change in any of oxidative stress parameters was noted in the TLC group. Ezetimibe may decrease markers of oxidative stress in hypercholesterolemic subjects. This benefit may be more profound among patients who exhibit 'high oxidative stress' at baseline.